Where does Heptares Therapeutics Limited rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Heptares Therapeutics Limited ranks #4,517 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Heptares Therapeutics Limited hold?

Heptares Therapeutics Limited holds 78 US utility patents granted between 2015 and 2024, spanning 9 technology areas.

What is Heptares Therapeutics Limited's Innovation Score?

Heptares Therapeutics Limited has an Innovation Score of 37.6 out of 100 (top 43% of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

Is Heptares Therapeutics Limited's patent grant rate increasing or decreasing?

Heptares Therapeutics Limited's recent grant velocity is -14% compared to the prior five-year period (grant years, not application filing dates). Grant activity has slowed relative to earlier years.

What does claim depth mean for Heptares Therapeutics Limited's patents?

Heptares Therapeutics Limited's patents average 15.4 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Heptares Therapeutics Limited patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView Foreign Corporation

Heptares Therapeutics Limited

Q: What technology areas does Heptares Therapeutics Limited focus on?

Heptares Therapeutics Limited's top technology area is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations) with 68 patents. Grants appear in 9 CPC subclasses total.

USPTO PatentsView assignee record - 78 granted patents across 9 technology areas, recorded in grant years 2015–2024. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Heptares ranks #4,517 of 49,997 tracked US assignees by granted-patent volume, with 78 patents across 9 technology areas.

#4,517
of 49,997 US assignees by volume: Top 43%
by Innovation Score (37.6/100): 15.4
avg claims per patent: -14%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R4517 · Foreign Corporation #4,517 · 78 grants

GRANTS-SMALL · TOP-DECILE · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-RICH · TYPE-FRNCORP · VEL-DOWN · BOOK-FULL

GRANTS-SMALL 78 grants
TOP-DECILE #4,517/49,997
PHOTO-FINISH Grote Industries
CPC-NARROW A61P · 9 areas
INNOV-THIN 37.6/100
CLAIMS-RICH 15.4 claims/avg
TYPE-FRNCORP Foreign Corp
VEL-DOWN -14% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: Grote Industries, Inc. (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

Qualcomm Incorporated · highest

85
Collision Communicat… · near

38
Heptares Therapeutics · this assignee

38
Cosmo · near

38
Shoretel · near

38
Summit Glove · near

38
3D Lighting… · lowest

7

What this shows Heptares's Innovation Score is 37.6/100 (top 43% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Where Heptares's grants concentrate

Heptares Therapeutics Limited is a focused PatentsView assignee: 9 CPC subclasses with 87.2% of grants classified under A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations). Peak complete grant year is 2019 (17 grants) versus a trough of 2 in 2015. By volume, Heptares sits between Grote Industries, Inc. and Keygene N.V..

Heptares's three-year grant acceleration

From 2019–2021 to 2022–2024, Heptares Therapeutics Limited moved from 38 to 15 grants (0.40x the prior three-year total, a multiple, not a CAGR). See the growth leaderboard.

Grote Industries

78
H B Fuller

78
Hongfujin Precisi…

78
Hanchett Entry Sy…

78
Indian Institute…

78
Interrad Medical

78
KAO Germany

78
Keygene

78
Heptares Therapeu… ◀

78

What this shows Heptares holds 78 patents at rank #4,518, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Heptares

By rank, the assignees closest to #4,518 in granted patent volume.

Leaders in A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…)

Other assignees with the most granted patents in Heptares's primary technology class.

Assignees with similar portfolio profiles

Two PlainPatent-derived peer sets for Heptares, neither rank-band nor same-CPC leaders (those blocks stay above).

Similar innovation score

Nearest assignees by Innovation Score (38 here).

Collision Communications, Inc. 38 Shoretel, Inc. 38 Summit Glove Inc. 38 Cosmo Technologies Ltd. 38

Similar claim depth

Nearest assignees by average claims per patent (15.4 here).

Somfy SAS 15.4 avg Imperial Innovations Limited 15.4 avg Shanghai Xiaodu Technology Co. Ltd. 15.4 avg Ememory Technology Inc. 15.4 avg

Heptares's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

38 Top 43% higher than 57% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2015–2024

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table

Heptares Therapeutics Limited patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2015	2	2.6%
2016	4	5.1%
2017	11	14.1%
2018	8	10.3%
2019	17	21.8%
2020	12	15.4%
2021	9	11.5%
2022	5	6.4%
2023	6	7.7%
2024	4	5.1%

Which technologies does Heptares Therapeutics Limited patent most?

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 68

C07D - Heterocyclic Compounds 67

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 37

C07K - Peptides 10

C07B - General Methods OF Organic CHEMISTRY; Apparatus Therefor 7

G01N - Investigating OR Analysing Materials BY Determining Their Chemical OR Physical Properties 7

C12N - Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media 5

C12Y - Enzymes 2

A61M - Devices FOR Introducing Media Into, OR Onto, THE Body ; Devices FOR Transducing Body Media OR FOR Taking Media From THE Body ; Devices FOR Producing OR Ending Sleep OR Stupor 1

Top 9 of 9 technology areas

Where it ranks

Overall rank by patents

#4,517

of 49,997 tracked assignees

Innovation Score

37.6 out of 100

View all rankings →

Data Source

USPTO PatentsView, US granted patents 2015–2025

How is Innovation Score calculated?

What to do with this data

Heptares Therapeutics Limited's patent record in context - here's where to go next.

Heptares Therapeutics Limited's lead technology class is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations), 87.2% of its portfolio - see every assignee active in that class. Explore A61P
Ranked #4,517 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Heptares Therapeutics Limited against Grote Industries, Inc., an assignee filing at a similar volume. Compare portfolios
Innovation Score of 37.6/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.